IDiyas

For the Inventor, By the Inventor

Banvaktsvagen, Sweden

Kancera Ab


USPTO Granted Patents = 15



Forward Citations = 57

Loading Chart...
Loading Chart...

33 inventors (with patents filed for the assignee):

goldMedal Jan Vågberg (9 out of 13 patents)

silverMedal Styrbjörn Byström (9 out of 12 patents)

bronzeMedal Elisabeth Olsson (6 out of 6 patents)

4.  Mattias Jönsson (5 out of 5 patents)

5.  Håkan Mellstedt (4 out of 4 patents)

6.  Jessica Martinsson (3 out of 3 patents)

7.  Rune Ringom (2 out of 9 patents)

8.  Kristin Hammer (2 out of 5 patents)

9.  Lars Krüger (2 out of 5 patents)

10.  Ingrid Teige (2 out of 11 patents)

11.  Katarina Färnegårdh (2 out of 2 patents)

12.  Katarina Faernegardh (2 out of 2 patents)

13.  Mattias Joensson (2 out of 2 patents)

14.  Evert Homan (1 out of 10 patents)

15.  Thomas Helleday (1 out of 11 patents)


15 patents:

1. 12264165 - Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom (2025-04-01),
2. 12060380 - Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 (2024-08-13),
3. 11691988 - Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom (2023-07-04),
4. 11660303 - 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (2023-05-30),
5. 11542281 - Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom (2023-01-03),
6. 11339183 - Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 (2022-05-24),
7. 11008318 - 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (2021-05-18),
8. 10654814 - Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity (2020-05-19),
9. 10550113 - 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity (2020-02-04),
10. 10512634 - Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity (2019-12-24),
11. 10000449 - Bisarylsulfonamides useful in the treatment of inflammation and cancer (2018-06-19),
12. 9718809 - Bisarylsulfonamides useful in the treatment of inflammation and cancer (2017-08-01),
13. 9266952 - Antibodies against ROR1 and uses thereof (2016-02-23),
14. 9233946 - Sulfonamide compounds (2016-01-12),
15. 9150647 - Biological inhibitors of ROR1 capable of inducing cell death (2015-10-06),
Kancera AB is a biotechnology company engaged in the research and development of innovative drugs for the treatment of cancer. The company focuses on identifying and targeting the underlying mechanisms of cancer cell survival and growth, aiming to develop effective therapies. Kancera AB utilizes cutting-edge technology and collaboration with partners in academia and industry to advance their drug candidates. With a dedicated team of scientists and experts, Kancera AB is committed to making a significant impact in the field of cancer treatment.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
15 Patents

#1 in Banvaktsvagen

#402 in Sweden

#38,669 in the World

...
Banvaktsvagen, Sweden

Kancera Ab

Forward Citations = 57

33 inventors:

goldMedal Jan Vågberg (9 out of 13 patents)

silverMedal Styrbjörn Byström (9 out of 12 patents)

bronzeMedal Elisabeth Olsson (6 out of 6 patents)

4.  Mattias Jönsson (5 out of 5 patents)

5.  Håkan Mellstedt (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com
Loading…